NASDAQ · NEO
Healthcare · Medical - Diagnostics & Research
$18.94
Up+$0.05 (+0.26%)
Updated Sep 17, 2026, 10:55 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NEO closed at $18.94 after 20 trading sessions, up 13.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $18.84 | $19.38 | $18.77 | $18.94 | 1.62M |
| Sep 15, 2026 | $18.40 | $19.29 | $18.40 | $18.89 | 2.43M |
| Sep 14, 2026 | $17.36 | $18.49 | $17.36 | $18.41 | 1.5M |
| Sep 11, 2026 | $17.85 | $17.92 | $17.21 | $17.32 | 1.07M |
| Sep 10, 2026 | $17.46 | $17.745 | $17.31 | $17.61 | 1.11M |
| Sep 9, 2026 | $17.28 | $17.995 | $17.15 | $17.66 | 1.54M |
| Sep 8, 2026 | $17.15 | $17.835 | $16.95 | $17.56 | 1.15M |
| Sep 4, 2026 | $17.20 | $17.47 | $16.865 | $17.38 | 997.01K |
| Sep 3, 2026 | $17.50 | $17.90 | $17.0542 | $17.46 | 2.25M |
| Sep 2, 2026 | $17.40 | $18.1763 | $17.26 | $17.40 | 1.79M |
| Sep 1, 2026 | $17.67 | $18.105 | $17.359 | $17.45 | 1.32M |
| Aug 31, 2026 | $17.77 | $18.075 | $17.19 | $17.91 | 1.58M |
| Aug 28, 2026 | $18.36 | $18.75 | $17.8938 | $18.05 | 1.72M |
| Aug 27, 2026 | $17.85 | $19.76 | $17.85 | $18.64 | 5.1M |
| Aug 26, 2026 | $16.69 | $17.455 | $16.58 | $17.37 | 1.68M |
| Aug 25, 2026 | $16.70 | $16.90 | $16.37 | $16.79 | 872.11K |
| Aug 24, 2026 | $16.75 | $16.80 | $16.28 | $16.41 | 1.1M |
| Aug 21, 2026 | $16.60 | $17.075 | $16.21 | $16.98 | 1.14M |
| Aug 20, 2026 | $16.18 | $16.82 | $15.98 | $16.53 | 2.75M |
| Aug 19, 2026 | $16.20 | $16.70 | $16.08 | $16.655 | 1.56M |
The latest Smart Investors Daily articles mentioning NEO.
NEO research
Company profile and research snapshot.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | Needham | Buy | — |
| Jul 24, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | TD Cowen | Buy | — |
| Apr 29, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
NeoGenomics, Inc. (NEO) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 7:45 AM EDTCompany ParticipantsAnthony Zook - CEO &...
Yahoo · Sep 11, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.
Yahoo · Sep 8, 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Yahoo · Sep 3, 2026
VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- AnorTech Inc. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc. Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the tota
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEO.
